FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966546013> ?p ?o ?g. }

• W2966546013 endingPage "14" @default.
• W2966546013 startingPage "1" @default.
• W2966546013 abstract "While the autoimmune character of T1D (type 1 diabetes) is being challenged, it is currently recognized that inflammation plays a key role in its development. We hypothesized that glucotoxicity could contribute to β -cell mass destruction through participation in islet inflammation. We evaluated the potential of empagliflozin (EMPA) and GABA (gamma-aminobutyric acid) to protect β -cell mass against glucotoxicity and to increase β -cell mass after diagnosis of T1D. Empagliflozin is a SGLT2 (sodium-dependent glucose cotransporter) inhibitor which thereby blocks glucose recapture by the kidney and promotes glucose excretion in urine. GABA is an inhibitory neurotransmitter, which stimulates α -to- β cell transdifferentiation. In streptozotocin-treated mice, empagliflozin and/or GABA were delivered for a period of five days or three weeks. As compared to untreated T1D mice, EMPA-treated T1D mice had decreased FFA (free fatty acid) levels and improved glucose homeostasis. EMPA-treated T1D mice had higher islet density, with preserved architecture, compared to T1D mice, and EMPA-treated T1D mice also differed from T1D mice by the total absence of immune cell infiltration within islets. Islets from EMPA-treated mice were also less subjected to ER (endoplasmic reticulum) stress and inflammation, as shown by qPCR analysis. Glucose homeostasis parameters and islet area/pancreas area ratio improved, as compared to diabetic controls, when T1D mice were treated for three weeks with GABA and EMPA. T1D EMPA+GABA mice had higher glucagon levels than T1D mice, without modifications of glucagon area/islet area ratios. In conclusion, empagliflozin and GABA, used in monotherapy in streptozotocin-induced diabetic mice, have positive effects on β -cell mass preservation or proliferation through an indirect effect on islet cell inflammation and ER stress. Further research is mandatory to evaluate whether empagliflozin and GABA may be a potential therapeutic target for the protection of β -cell mass after new-onset T1D." @default.
• W2966546013 created "2019-08-13" @default.
• W2966546013 creator A5001070307 @default.
• W2966546013 creator A5014249717 @default.
• W2966546013 creator A5038401549 @default.
• W2966546013 creator A5044205198 @default.
• W2966546013 creator A5044518485 @default.
• W2966546013 creator A5050657323 @default.
• W2966546013 creator A5064747309 @default.
• W2966546013 date "2019-07-30" @default.
• W2966546013 modified "2023-10-03" @default.
• W2966546013 title "Early Treatment with Empagliflozin and GABA Improves <i>β</i>-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice" @default.
• W2966546013 cites W1480273589 @default.
• W2966546013 cites W1946307024 @default.
• W2966546013 cites W1976422365 @default.
• W2966546013 cites W2001276968 @default.
• W2966546013 cites W2003771230 @default.
• W2966546013 cites W2010154622 @default.
• W2966546013 cites W2013048175 @default.
• W2966546013 cites W2016839547 @default.
• W2966546013 cites W2017934798 @default.
• W2966546013 cites W2020629155 @default.
• W2966546013 cites W2021568006 @default.
• W2966546013 cites W2027545319 @default.
• W2966546013 cites W2032451121 @default.
• W2966546013 cites W2048211245 @default.
• W2966546013 cites W2050397606 @default.
• W2966546013 cites W2054513303 @default.
• W2966546013 cites W2057692152 @default.
• W2966546013 cites W2080889881 @default.
• W2966546013 cites W2083485319 @default.
• W2966546013 cites W2087435915 @default.
• W2966546013 cites W2099670937 @default.
• W2966546013 cites W2113544353 @default.
• W2966546013 cites W2119405541 @default.
• W2966546013 cites W2123706153 @default.
• W2966546013 cites W2124136509 @default.
• W2966546013 cites W2126780067 @default.
• W2966546013 cites W2129387684 @default.
• W2966546013 cites W2130116897 @default.
• W2966546013 cites W2132046208 @default.
• W2966546013 cites W2138364630 @default.
• W2966546013 cites W2147497390 @default.
• W2966546013 cites W2150550074 @default.
• W2966546013 cites W2173615285 @default.
• W2966546013 cites W2175219657 @default.
• W2966546013 cites W2188217851 @default.
• W2966546013 cites W2189696564 @default.
• W2966546013 cites W2264545185 @default.
• W2966546013 cites W2323566388 @default.
• W2966546013 cites W2550835414 @default.
• W2966546013 cites W2559389868 @default.
• W2966546013 cites W2564078202 @default.
• W2966546013 cites W2604852286 @default.
• W2966546013 cites W2610296209 @default.
• W2966546013 cites W2619744261 @default.
• W2966546013 cites W2626083631 @default.
• W2966546013 cites W2756343181 @default.
• W2966546013 cites W2784171922 @default.
• W2966546013 cites W2795214533 @default.
• W2966546013 cites W2801478978 @default.
• W2966546013 cites W2809595382 @default.
• W2966546013 cites W2890505772 @default.
• W2966546013 cites W2894624538 @default.
• W2966546013 cites W4240175730 @default.
• W2966546013 cites W4242514389 @default.
• W2966546013 doi "https://doi.org/10.1155/2019/2813489" @default.
• W2966546013 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6701376" @default.
• W2966546013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31467926" @default.
• W2966546013 hasPublicationYear "2019" @default.
• W2966546013 type Work @default.
• W2966546013 sameAs 2966546013 @default.
• W2966546013 citedByCount "20" @default.
• W2966546013 countsByYear W29665460132020 @default.
• W2966546013 countsByYear W29665460132021 @default.
• W2966546013 countsByYear W29665460132022 @default.
• W2966546013 countsByYear W29665460132023 @default.
• W2966546013 crossrefType "journal-article" @default.
• W2966546013 hasAuthorship W2966546013A5001070307 @default.
• W2966546013 hasAuthorship W2966546013A5014249717 @default.
• W2966546013 hasAuthorship W2966546013A5038401549 @default.
• W2966546013 hasAuthorship W2966546013A5044205198 @default.
• W2966546013 hasAuthorship W2966546013A5044518485 @default.
• W2966546013 hasAuthorship W2966546013A5050657323 @default.
• W2966546013 hasAuthorship W2966546013A5064747309 @default.
• W2966546013 hasBestOaLocation W29665460131 @default.
• W2966546013 hasConcept C126322002 @default.
• W2966546013 hasConcept C134018914 @default.
• W2966546013 hasConcept C138411078 @default.
• W2966546013 hasConcept C165220095 @default.
• W2966546013 hasConcept C185592680 @default.
• W2966546013 hasConcept C199289684 @default.
• W2966546013 hasConcept C2775887513 @default.
• W2966546013 hasConcept C2777180221 @default.
• W2966546013 hasConcept C2777391703 @default.
• W2966546013 hasConcept C2778563252 @default.
• W2966546013 hasConcept C2779280383 @default.
• W2966546013 hasConcept C2779306644 @default.

• next